Understand how InferTrust™ decision records enable faster, more precise responses to FDA Form 483 inspectional observations involving AI/ML-based medical device
Form 483 observations are issued at the conclusion of an FDA inspection when investigators identify conditions that may violate the Food, Drug, and Cosmetic Act. For AI medical device manufacturers, 483 observations often involve design control deficiencies, inadequate validation documentation, insufficient complaint handling for algorithm errors, or gaps in post-market surveillance. InferTrust™ FDA Enforcement (Patent Pending) transforms how manufacturers respond to these observations.
When a 483 observation cites an algorithm-related deficiency, the first step is identifying the root cause. With conventional logging, this requires forensic reconstruction from multiple systems. With InferTrust™, the manufacturer can examine the sealed decision records for the relevant time period and identify exactly when the algorithm deviated from expected behavior, which model version was responsible, what confidence scores it was producing, and whether escalation policies were triggered appropriately. This precision enables root cause identification in hours rather than weeks.
The 483 response must document the corrective action and provide evidence of implementation. InferTrust™ decision records show the exact point in the decision chain where the corrective action took effect: the new model version hash, the updated validation results, and the post-correction performance metrics. Because these records carry the same cryptographic guarantees as all InferTrust™ records, FDA can verify the corrective action with confidence.
Effective 483 responses demonstrate not just correction but prevention. InferTrust™ supports CAPA documentation by providing ongoing decision records that demonstrate sustained compliance after the corrective action. Performance trends, model stability metrics, and escalation frequency data are all available in the sealed record chain, supporting the manufacturer's demonstration that the corrective action effectively prevents recurrence.